Page 41 - Demo456

White Papers
Download the White Paper
CHALLENGES IN CHALL
http://bit.ly/2V9YgVm_PM360
THOUGHT LEADER MANATGHEOMUEGNHT LEAD
Identify & Manage the Right Key Opinion
Tdecade, including the emergent power of mana
Leaders for Your Brand
he pharmaceutical industry has been reshaped byhmeapnhyarcmhancgeeutsicoavleinrdtuhsetrpyahsat
ta andredpigreitsaelnptlatifvoerms,sanads mthaerkeextpinlogsive gr representatives, and the explosive growth of da
tools. One key aspect of the business that has remationoelds cOonsetaknety haospwecvteorfitshtehebunseineedss that
Data Analytics And gage for pharmaceutical companies to engage with t
These changes are necessary because of the increased
increasingly difficult to engage with the right leaders
competition for thought leaders’ time. Therefore, thoughtful engagement planning and tracking, along with more
due to the increased competition for KOLs’ time, the
clearly defined roles for relationship owners, are becoming
globalization of the industry, increased compliance
increasingly important.
Th recape
restrictionAst,thaensdamtheetimne,eredcetontisdhieftnstiniftyhenpehwarmthaolaundgshctape have made thought leader management in 2018 a complex
fiv complex pr
leaders as the “baby boomer” generation of KOLs
task rife with challenges, including:
ou
are engaging
e world ompany
o work
start to ret•iTrhee. globalization of the industry—companies are engaging thought leaders to consult on activities all over the world
do • The increased compliance requirements that accompany Th such geographic expansion ev
• The demand across functions within companies to work ou
with the same thought leaders and executiwonit,hdtohseinsga,mdeltihvoeuryg,hctolmeapdliearnsce, publications,
• The pending retirement of the “baby boomer” thought leaders and the need to identify younger, up-and-coming experts
s bee Tged cdaercea,dthee, idneclculidniingtuhseeeomfesraglesnt pow
.,, houghfotrlepahdaermrsa.ceuticalcompaniestoen
CHALLENGES IN armaceAutlsicoalkcnomwpnaansiekseythoapt ihnaiovne lceraedaetersd, ionrteKrOnaLls, these
THOUGHT LEADER MANAGEMENT erationsindfleudeinccaetemdetodimcalnpargacintgicethaonudghptalteieandtecrare region
gagemennatiaorneafillny,doinrgltohbaatlslyo.luPthioanrmsatoatnhdesbeioctehcahllecnogmepsan
collaborate with thought leaders at every phase of in data analytics and technology.
development and commercialization to ensure that
idan
g
lie in data analytics and technology.
pera
“oItuigshAotn“lMeUaoSdTfe-HtrhAsVe’Et”cimore. Tphieecresfoorfe, th
TnGeeHdsTarLeEbeAingDmEeRt.S
HOU
al
nr
col
t
t
ne
te
THOUGHT LEADERS
is r
h
labo
c
eds
are
be
t
e
i
e
h
fle
v
ct
he
decade, including the emergent power of managed care, the declining use of sales
ra
e
t
io
d
c
e
natnaagreethtohuagt hset elekaindgerthrelations
ew
oT
e s
e c
o
d in
t
i
singly important.
n
f
n
pha
hf
ing
m
of
pt e
u
t
y
o
h
r
t
c
such geographic expansion
rly
h
r
rmac
r m
h
i
d
e
inc
e
ou
t
.
e
re
g
h
a
t le
a
eutic
indu
se
rt
sn
et i
fs o
The importance of engaging with the right thought leaders
d
a
ategic aenndglaguenmchenretapdlainensinsgp
a
s
a
anddedicated staff to manage thought leader relationships.
c
,
,
e
D
e
co
i
r
e
c
e
e
. h
p
re b
c
l
lua
s
t
o
t
J
a
l
d
r
ay
s
n
P
l
a
de
edaysahawveemk,adretimhopuogrthatnletat
c
o
e8nat 1
t
n
t
t
r
ino
r
te
s
’t
nti
a
e
im
o
n
fi
n
pla
e
T
s
n
r
.
,
,
a
r
yp
h
c
stry
has
bee
eshaped by many changes over the past
The importance of engaging with the right thought
“MUisSreTfl-eHcteAdVinEthe”increasedattentionplacedonth tools. One key aspect of the business that has remained constant, however, is the need
representatives, and the explosive growth of data and digital platforms as marketing
hough tbhyepsehacromapandiebsiomtaeychacvoemvparnieiedsa, wpphroahcahvesnot
for pharmaceutical companies to engage with thought leaders.
Also known as key opinion leaders, or KOLs, these experts Pharmaceutical companies that have created internal
d differenxtpiasnsduesdtoheadrodlresosf,mtheedpicraolfsecsiseionncealsliainisochnasrbguet
thou
influence medical practice and patient care regionally, operations dedicated to managing thought leader nationally, or globally. Pharma and biotech companies engagement are finding that solutions to these challenges
g
h
t
le
m
da
a
e
id
ea
er
gff
mo
e
de e
eh
has
d
o
efo
e
o
n
t
re
th
h
.
f dru
o
em
o
u
em
d
escehmanegdeicsaal erexpnerctessrseamryaibnescahuisgeho-vfatlhueincre
ith
development and commercialization to ensure that patient
tho
u
gh
t le
a
d
er
sa
te
ve
by pharma and biotech companies, who have not only Although these companies may have varied approaches expanded the role of medical science liaisons but have also and different issues to address, the professionals in charge
f
These changes are necessary because of the increased guidance of these medical experts remains a high-value
l
i
o
clearly defined roles for relationship owners, are becoming Brand Director at Janssen Pharmaceuticals.
gh
as
r fmo
s engagement planning and tracking, along with more strategic and launch readiness plans,” says Marina Tribble,
co
of
mp
e
tit
tful
.
ought leaders, whether they are extensively published
increasing
ly
im
po
rt
ant
.
Thought leaders, whether they are extensively published
At the same time, recent shifts in the pharma landscape researchers or “worker bee” physicians who see patients
searcheArst othre“wsaomrkertibmee,”repcheynsticsiahnifstswinhothseepehpaarmtieanltasnds
have made thought leader management in 2018 a complex five days a week, are important to the product development
task rife with challenges, including: process. The industry needs to rely on the medical experts • The globalization of the industry—companies are engaging out there who are dealing with patients. Pharma companies
thought leaders to consult on activities all over the world do that is to get advice and information from the experts.
ocess. Tthaeskinrdifeuswtriythnceheadlsletnogre
,
• The increased compliance requirements that accompany
T
l
d
n
:
t there who are dealing with patients. Pharma companies
• The demand across functions within companies to work outcomes as the goal. Their input is sought on trial design
• The globalization of t
with the same thought leaders and execution, dosing, delivery, compliance, publications,
trying to make patients’ lives
b
h
a
• The pending retirement of the “baby boomer” thought leaders
Th
Ma
,
,
and the need to identify younger, up-and-coming experts
,
any
that is to get advice and information from the experts.
• The increased compliance requirements that acc ought leaders are consulted by companies on nearly
such geographic expansion
ery aspect of the product lifecycle, with optimal patient
tcomes•aTshtehedegmoaln. Tdhaeciroinsspufut nisctsioungs hwtiothnintrciaolmdpeasingiens t
750 ThirdAvenue, Suite 1003 New York, NY, 10017 (212)661-7685 info@81qd.com 81qd.com
o
th
le
a
g
al
ky
b
im
s
a
ra r
t
pe
o d
p
re
try
e
h
s
no c
ut
ei
mg
h
p
d mo
iser
ati
o
l
n
h
e
u
oug
n
n
t”
lion
o
r
u
a
gh
e
i
e
ent c
g
ti
s
a
r
T
i
d
r
ht
a
ve
for
th
h
et r
no
mt
e
e
m
in
,y i
erts
ht
L
t
lea
g
t
t
y to thought leaders to consult on activities all over th
o
e
d
o
ma
n
t
ea
d
m
a
e
d
e
mm
e
d
de
a
e
rs
a
i
an
r
a
un
r
na
r
m
e
in
a
e
vt n
nl i
2p 0
k
e
p
u
ica
c
n
a
g
i
r
d
r
a
nag
du
ati
ec
s
tio
s
e
o
t
n
ns
an
re.
Pa
si
Mg
an
rw
tbhlem,or
nt
e
try
“It
i
nsu
r
ge
m
s
’l
y
c
u
d
e
b
ent
a
lte
iv
every aspect of the product lifecycle, with optimal patient
ment
,a
s on
es
be
d
by
co
t
—
v
g
r
d
tE
ee
tha
eo
t
ter
an
o
i
m
li Lill
w
f the
co
c
pa
m
t se
n
a
tti H
ya
d
th
nie
l
e
p
e
e
so
oga
nd
Co
kin
e
re
pi
e
b
a
s
n
nea
r
t
w
n,
Ad
g
t
ece
es
x
n
mp
h
tw
p
i
e
a
,
y
to
s
are
Technology Can Help
Also known as key opinion leaders, or KOLs, these experts Ph experts
influence medical practice and patient care regionally, op ally,
nationally, or globally. Pharma and biotech companies en ies
Key opinion leaders (KOLs), or thought leaders,
collaborate with thought leaders at every phase of drug lie drug
remain andiemveploopmrteannt tanpdacrotmnmererfcoiarlizpahtioanrmto eancsuorme tphatnpiaetisent needs are being met.
patient The importance of engaging with the right thought leaders leaders
as they are consulted on nearly every aspect of the T
product lifecycle, including trial design and execution,
Aem
Alt only
an have also ofhips. guased imoughtful stre Brecoming
is reflected in the increased attention placed on them
by pharma and biotech companies, who have not only
dosing, delivery, compliance, publications, patient
expanded the role of medical science liaisons but have also communidceadticoantesd, satnaffdtommoarnea.geHthoowugehvteler,aditerisreblaeticoonsmhipins.g
patient communications, and more. Patti Hogan, Adviser,
• The pending retirement of the “baby boomer” thought leaders
Thought Leader Management, at Eli Lilly and Company,
and the need to identify younger, up-and-coming experts
750 ThirdAvenue, Suite 1003 New York, NY, 10017
(212)661-768750 ThirdAveninufeo,@S8u1itqed1.0co0m3 New York, N8Y1,q1d0.c0o17m
E E
n e o
w